Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.
Maiorano BA, Catalano M, Mercinelli C, Roviello G, Maruzzo M, De Giorgi U, Chiellino S, Sbrana A, Galli L, Zucali PA, Masini C, Naglieri E, Procopio G, Merler S, Fratino L, Baldessari C, Ricotta R, Mollica V, Sorarù M, Tudini M, Prati V, Malgeri A, Atzori F, Napoli MD, Caffo O, Spada M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Lipari H, Puglisi S, Signori A, Necchi A, Banna GL, Fornarini G, Buti S, Rebuzzi SE. Maiorano BA, et al. Among authors: naglieri e. Clin Genitourin Cancer. 2024 Nov 10;23(1):102267. doi: 10.1016/j.clgc.2024.102267. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39603144
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
Rebuzzi SE, Signori A, Banna GL, Maruzzo M, De Giorgi U, Pedrazzoli P, Sbrana A, Zucali PA, Masini C, Naglieri E, Procopio G, Merler S, Tomasello L, Fratino L, Baldessari C, Ricotta R, Panni S, Mollica V, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Stellato M, Atzori F, Pignata S, Messina C, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Pierantoni F, Casadei C, Bersanelli M, Chiellino S, Paolieri F, Perrino M, Brunelli M, Iacovelli R, Porta C, Buti S, Fornarini G. Rebuzzi SE, et al. Among authors: naglieri e. Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34046089 Free PMC article.
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
Raggi D, Giannatempo P, Marandino L, Pierantoni F, Maruzzo M, Lipari H, Banna GL, De Giorgi U, Casadei C, Naglieri E, Buti S, Bersanelli M, Stellato M, Santini D, Vignani F, Roviello G, Veccia A, Caffo O, Losanno T, Calabrò F, Mucciarini C, Pignata S, Necchi A, Maio MD; MEET-URO Group. Raggi D, et al. Among authors: naglieri e. Clin Genitourin Cancer. 2022 Apr;20(2):155-164. doi: 10.1016/j.clgc.2021.12.008. Epub 2021 Dec 16. Clin Genitourin Cancer. 2022. PMID: 35000876
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Roviello G, et al. Among authors: naglieri e. Cancer Med. 2022 Aug;11(16):3084-3092. doi: 10.1002/cam4.4681. Epub 2022 Mar 20. Cancer Med. 2022. PMID: 35312175 Free PMC article.
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
Rebuzzi SE, Signori A, Banna GL, Gandini A, Fornarini G, Damassi A, Maruzzo M, De Giorgi U, Basso U, Chiellino S, Galli L, Zucali PA, Fantinel E, Naglieri E, Procopio G, Milella M, Boccardo F, Fratino L, Pipitone S, Ricotta R, Panni S, Mollica V, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Santini D, Atzori F, Di Napoli M, Caffo O, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Rescigno P, Buti S. Rebuzzi SE, et al. Among authors: naglieri e. J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6. J Transl Med. 2022. PMID: 36180954 Free PMC article.
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab.
Catalano M, Rebuzzi SE, Maruzzo M, De Giorgi U, Buti S, Galli L, Fornarini G, Zucali PA, Procopio G, Chiellino S, Milella M, Catalano F, Pipitone S, Ricotta R, Sorarù M, Mollica V, Tudini M, Fratino L, Prati V, Caffo O, Atzori F, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Di Napoli M, Malgeri A, Naglieri E, Signori A, Banna GL, Rescigno P, Antonuzzo L, Roviello G. Catalano M, et al. Among authors: naglieri e. JAMA Netw Open. 2023 Nov 1;6(11):e2345185. doi: 10.1001/jamanetworkopen.2023.45185. JAMA Netw Open. 2023. PMID: 38010650 Free PMC article.
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.
Murianni V, Signori A, Buti S, Rebuzzi SE, Bimbatti D, De Giorgi U, Chiellino S, Galli L, Zucali PA, Masini C, Naglieri E, Procopio G, Milella M, Fratino L, Baldessari C, Ricotta R, Mollica V, Sorarù M, Tudini M, Prati V, Malgeri A, Atzori F, Di Napoli M, Caffo O, Spada M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Lipari H, Roviello G, Catalano F, Damassi A, Cremante M, Rescigno P, Fornarini G, Banna GL. Murianni V, et al. Among authors: naglieri e. Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024. Front Oncol. 2024. PMID: 38410103 Free PMC article.
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study).
Rebuzzi SE, Fornarini G, Signori A, Buti S, Procopio G, De Giorgi U, Pignata S, Naglieri E, Maruzzo M, Banna GL, Rescigno P, Messina C, Mattana A, Basso U, Bimbatti D. Rebuzzi SE, et al. Among authors: naglieri e. BMC Cancer. 2024 Jun 24;24(1):757. doi: 10.1186/s12885-024-12319-1. BMC Cancer. 2024. PMID: 38914928 Free PMC article.
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.
Messina C, Catalano M, Roviello G, Gandini A, Maruzzo M, De Giorgi U, Pedrazzoli P, Sbrana A, Zucal PA, Masini C, Naglieri E, Procopio G, Milella M, Catalano F, Fratino L, Pipitone S, Ricotta R, Panni S, Mollica V, Soraru M, Prati V, Atzori F, Di Napoli M, Messina M, Morelli F, Prati G, Nole F, Malgeri A, Tudini M, Vignani F, Cavo A, Signori A, Banna GL, Rescigno P, Buti S, Rebuzzi SE, Fornarini G. Messina C, et al. Among authors: naglieri e. Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2. Cancer Immunol Immunother. 2024. PMID: 38954006 Free PMC article.
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.
Catalano M, Rebuzzi SE, Maruzzo M, De Giorgi U, Buti S, Galli L, Fornarini G, Zucali PA, Claps M, Chiellino S, Zampiva I, Pipitone S, Ricotta R, Sorarù M, Mollica V, Tudini M, Fratino L, Prati V, Caffo O, Atzori F, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Di Napoli M, Malgeri A, Naglieri E, Signori A, Banna GL, Rescigno P, Cerbone L, Antonuzzo L, Roviello G. Catalano M, et al. Among authors: naglieri e. Front Immunol. 2024 Jul 5;15:1361010. doi: 10.3389/fimmu.2024.1361010. eCollection 2024. Front Immunol. 2024. PMID: 39034992 Free PMC article.
56 results